BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Greuter T, Hirano I, Dellon ES. Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol 2020;145:38-45. [PMID: 31705907 DOI: 10.1016/j.jaci.2019.10.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Xiao X, Liu D, Tan C. A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide. Ann Med 2022;54:2078-88. [PMID: 35862288 DOI: 10.1080/07853890.2022.2101689] [Reference Citation Analysis]
2 Dellon ES, Tsai YS, Coffey AR, Bodwin K, Sninsky JA, Mosso CN, He TM, O'Connor KA, Selitsky SR, Nobel AB, Parker JS. Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis. Dis Esophagus 2022:doac071. [PMID: 36222072 DOI: 10.1093/dote/doac071] [Reference Citation Analysis]
3 Chen X, Ding X, Ko HM. Non-esophageal eosinophilic gastrointestinal disorders. Human Pathology Reports 2022;29:300655. [DOI: 10.1016/j.hpr.2022.300655] [Reference Citation Analysis]
4 Chan R, Stewart K, Misirovs R, Lipworth BJ. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma. J Allergy Clin Immunol Pract 2022;10:1497-505. [PMID: 35131510 DOI: 10.1016/j.jaip.2022.01.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, Collins MH, Gonsalves N, Falk GW, Spergel JM, Hirano I, Chehade M, Schoepfer AM, Menard-Katcher C, Katzka DA, Bonis PA, Bredenoord AJ, Geng B, Jensen ET, Pesek RD, Feuerstadt P, Gupta SK, Lucendo AJ, Genta RM, Hiremath G, McGowan EC, Moawad FJ, Peterson KA, Rothenberg ME, Straumann A, Furuta GT, Aceves SS. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology 2022:S0016-5085(22)00287-6. [PMID: 35606197 DOI: 10.1053/j.gastro.2022.03.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Sher ER, Ross JA, Weine DM, Chandini Arjun A. Current and emerging therapies for eosinophilic esophagitis. Allergy Asthma Proc 2022;43:178-86. [PMID: 35524356 DOI: 10.2500/aap.2022.43.220014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, Collins MH, Gonsalves N, Falk GW, Spergel JM, Hirano I, Chehade M, Schoepfer AM, Menard-katcher C, Katzka DA, Bonis PA, Bredenoord AJ, Geng B, Jensen ET, Pesek RD, Feuerstadt P, Gupta SK, Lucendo AJ, Genta RM, Hiremath G, Mcgowan EC, Moawad FJ, Peterson KA, Rothenberg ME, Straumann A, Furuta GT, Aceves SS. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Journal of Allergy and Clinical Immunology 2022. [DOI: 10.1016/j.jaci.2022.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dellon ES, Simon D, Wechsler ME. Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders. J Allergy Clin Immunol Pract 2022;10:1169-76. [PMID: 35167955 DOI: 10.1016/j.jaip.2022.01.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lam AY, Ma C, Lee JK, Bredenoord AJ. Eosinophilic esophagitis: New molecules, better life? Curr Opin Pharmacol 2022;63:102183. [PMID: 35176546 DOI: 10.1016/j.coph.2022.102183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang S, Sicherer S, Berin MC, Agyemang A. Pathophysiology of Non-IgE-Mediated Food Allergy. Immunotargets Ther 2021;10:431-46. [PMID: 35004389 DOI: 10.2147/ITT.S284821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kuźmiński A, Przybyszewski M, Przybyszewska J, Bartuzi Z. Eosinophilic esophagitis. What diet? How to treat it? The point of view of a gastroenterologist working in a department of allergology. Prz Gastroenterol 2021;16:318-23. [PMID: 34976239 DOI: 10.5114/pg.2021.105163] [Reference Citation Analysis]
12 Chehade M, Falk GW, Aceves S, Lee JK, Mehta V, Leung J, Shumel B, Jacob-nara JA, Deniz Y, Rowe PJ, Cunoosamy D, Khodzhayev A. Examining the Role of Type 2 Inflammation in Eosinophilic Esophagitis. Gastro Hep Advances 2022;1:720-732. [DOI: 10.1016/j.gastha.2022.05.004] [Reference Citation Analysis]
13 Beauchemin C, Castonguay A, Chan ES, Dellon ES, Feagan BG, Ma C, Waserman S, Cook J, Claveau D. Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost-Utility Analysis. Adv Ther 2021;38:5737-51. [PMID: 34699003 DOI: 10.1007/s12325-021-01957-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
14 Dunn JLM, Rothenberg ME. 2021 year in review: Spotlight on eosinophils. J Allergy Clin Immunol 2021:S0091-6749(21)01796-6. [PMID: 34838883 DOI: 10.1016/j.jaci.2021.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ketchem CJ, Thakkar KP, Xue A, Reddy S, Abramson L, Greenberg SB, Abichandani S, Miller TL, Chang NC, Eluri S, Reed CC, Dellon ES. Older patients with eosinophilic esophagitis have high treatment response to topical steroids. Dig Liver Dis 2021:S1590-8658(21)00809-4. [PMID: 34789398 DOI: 10.1016/j.dld.2021.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kanikowska A, Hryhorowicz S, Rychter AM, Kucharski MA, Zawada A, Iwanik K, Eder P, Słomski R, Dobrowolska A, Krela-Kaźmierczak I. Immunogenetic, Molecular and Microbiotic Determinants of Eosinophilic Esophagitis and Clinical Practice-A New Perspective of an Old Disease. Int J Mol Sci 2021;22:10830. [PMID: 34639170 DOI: 10.3390/ijms221910830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Robinson KJ. Eosinophilic Esophagitis. Physician Assistant Clinics 2021;6:593-602. [DOI: 10.1016/j.cpha.2021.05.004] [Reference Citation Analysis]
18 Franceschini L, Macchiarelli R, Biviano I, Farsi A. Eosinophilic Esophagitis Onset Despite Six Years' Treatment With Omalizumab in an Asthmatic Patient: No Protective Effect for Anti-IgE Therapy? Am J Gastroenterol 2021;116:1560. [PMID: 33852452 DOI: 10.14309/ajg.0000000000001213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Miehlke S, von Arnim U, Schlag C, Labenz J, Madisch A. [Treatment of eosinophilic esophagitis - advancements and perspectives]. Z Gastroenterol 2021;59:869-78. [PMID: 34157757 DOI: 10.1055/a-1429-4192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Greenberg S, Chang NC, Corder SR, Reed CC, Eluri S, Dellon ES. Dilation-predominant approach versus routine care in patients with difficult-to-treat eosinophilic esophagitis: a retrospective comparison. Endoscopy 2021. [PMID: 33910259 DOI: 10.1055/a-1493-5627] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Odiase E, Zhang X, Chang Y, Nelson M, Balaji U, Gu J, Zhang Q, Pan Z, Spechler SJ, Souza RF. In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump. Gastroenterology 2021;160:2072-2088.e6. [PMID: 33581123 DOI: 10.1053/j.gastro.2021.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
22 Kim SJ, Park MI, Kim GH, Lee MW, Jung K, Lee J, Seol SY, Jee SR, Lee HS, Jang JS, Cha JH; Gyeongnam Society of Neurogastroenterology and Motility. Practice Patterns for Eosinophilic Esophagitis Patients in Busan and Gyeongnam: A Korean Multicenter Database Study. J Neurogastroenterol Motil 2021;27:71-7. [PMID: 32699187 DOI: 10.5056/jnm20069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Dellon ES. Red Between the Lines: Evolution of Eosinophilic Esophagitis as a Distinct Clinicopathologic Syndrome. Dig Dis Sci 2020;65:3434-47. [PMID: 33052498 DOI: 10.1007/s10620-020-06642-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Madison JM, Bhardwaj V, Braskett M. Strategy for Food Reintroduction Following Empiric Elimination and Elemental Dietary Therapy in the Treatment of Eosinophilic Gastrointestinal Disorders. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-00758-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Oliva S, Azouz NP, Stronati L, Rothenberg ME. Recent advances in potential targets for eosinophilic esophagitis treatments. Expert Rev Clin Immunol 2020;16:421-8. [PMID: 32163308 DOI: 10.1080/1744666X.2020.1742110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Sugita K, Kabashima K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. J Leukoc Biol 2020;107:749-62. [PMID: 32108379 DOI: 10.1002/JLB.5MR0120-230R] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 17.5] [Reference Citation Analysis]
27 Aceves S, Collins MH, Rothenberg ME, Furuta GT, Gonsalves N; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). J Allergy Clin Immunol 2020;145:28-37. [PMID: 31758958 DOI: 10.1016/j.jaci.2019.11.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]